The conventional pharma R&D model is broken, taking many years and $billions for approved medicine with high failure rates in clinic. A new approach is needed.See Our Story
We embrace the true complexity of biology. Our network-driven drug discovery ("NDD") approach uses a powerful informatics platform based on sophisticated big data analysis, machine learning and AI.See Our Approach
We seek collaborations focused on the commercialisation of our NDD platform, creating and licensing NDD discovery programmes as well as out-licensing our own NDD-derived assets.See Our Business Model
We are an Oxford, UK-based business with a revolutionary computer-based platform and a unique network-driven drug discovery ("NDD") methodology which allows us to discover novel and better drugs faster.Who we are
Read more about our cutting edge in silico techniques, the importance of network science, our strategy and our assets.What we do
View our regulatory announcements, read our publications, see our videos and subscribe to receive email alerts.News & media
We are a UK-based company listed (ETX.L) on the Alternative Investment Market (AIM), London Stock Exchange's international market for smaller, growing companies.Investors
Share price6.75p Share price information
Latest Report 20182018 Annual Report
Research Collaboration Agreement with Novo Nordisk
MiscellaneousLatest Regulatory Announcements
Partnering & Collaboration
Our NDD approach consistently generates potent and novel hits, assisting companies increase the productivity of their drug discovery.
Please get in touch at firstname.lastname@example.org.